Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Agopton, Lansobene, Lansohexal, Lansonorm, Lansoprazol; Belgium: Dakar, Lansoprazol, Lansoprazole; Bulgaria: Lansoprol; Cyprus: Lasoprol; Czech Republic: Lansoprazol, Lansoprol, Lansoram, Lanzul; Denmark: Lansoprazol; Estonia: Lanobax, Lansoprazol, Lanzostad, Lanzul; Finland: Gasterix, Helipak, Lanrec, Lansoprazol, Lantil, Lanvone, Prazotad, Sepol, Zolt; France: Lansoprazole, Lanzor, Ogast, Ogastoro; Germany: Agopton; Lanso, Lansoprazol, Lansosiga, Lansox, Lanzoprazol, Lanzor, Zoton; Greece: Apradil, Lanciprol, Lanso, Lanzol, Laprazol, Prevacid, Ulced, Zoletad; Hungary: Lansone; Ireland: Bylans, Lansoprazole, Lanziop, Lanzol, Razolager, Zomel, Zoton, Zotrole; Italy: Ermes, Eugastran, Frilans, Krovaneg, Lansoprazolo, Lansox, Levogenix, Limpidex, Lomevel, Peptirex, Pergastid, Zoton; Latvia: Lanobax, Lansoprazol, Lanzole, Lanzostad, Lanzul, Pylokit; Lithuania: Lanobax, Lansoprazol, Lanzostad, Lanzul; Luxembourg: Dakar; Malta: Lasoprol, Lansoprazole; Netherlands: Lansoprazol, Lanzatol, Ogastro, Prezal; Poland: Lanbax, Lansolek, Lansoprazole, Lansoprazolum, Lantrea, Lanzogen, Lanzostad, Lanzul, Opatin, Rapilazole, Renazol, Zalanzo; Portugal: Alexin, Belmural, Dispepci, Gastrex, Gastribien, Gastroliber, Lansoprazol, Lanzogastro, Lapol, Ogasto, Pampe, Ulcertec; Romania: Lansoprazol, Lanzap, Lanzogastro, Lanzol; Lanzul, Levant-Ranbaxy; Slovakia: Lansoprazole, Lansoram, Lanzul; Slovenia: Lansoprazol, Lantrea, Lanzul; Spain: Bamalite, Estomil, Lansoprazol, Lanzol, Monolitum, Opiren, Pasgram, Pro-Ulco, Protoner; Sweden: Lanipizin, Lansolidix, Lansoprazol, Lanzo, Linepizin, Nixacid, Zoton; UK: Lansoprazole, Zoton.

North America

Canada: Lansoprazole, Prevacid; USA: Lansoprazole, Prevacid.

Latin America

Argentina: Lanzoacid, Lanzopral, Mesactol; Brazil: Alkazol, Lanogastro, Lansoprazol, Lanz, Lanzol, Lanzopept, Neozol, Ogastro, Prazol-Medley; Mexico: Amdory, Arular, Bonzol, Gavonad, Ilsatec, Imidex, Keval, Lafin, Lanodizol, Lansoprazol, Mavilan, Mediprim, Ogastro, Olan, Palatrin, Pranix, Safemar, Serax, Uldapril, Ulpax.


Japan: Lansoprazole, Lansoral, Laprazol, Lasopran, Stanzome, Taiproton, Takepron, Tapizol.

Drug combinations

Lansoprazole and Naproxen

Lansoprazole, Amoxicillin, and Clarithromycin

Lansoprazole, Amoxicillin, and Metronidazole

Lansoprazole, Metronidazole, and Tetracycline


Lansoprazole: C~16~H~14~F~3~N~3~O~2~S. Mw: 369.36. (1) 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-; (2) 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole. CAS-103577-45-3 (1989).

Pharmacologic Category

Antiulcer Agents and Acid Suppressants; Proton-pump Inhibitors; Substituted Benzimidazole. (ATC-Code: A02BC03).

Mechanism of action

Decreases acid secretion in gastric parietal cells through inhibition of (H^+^, K^+^)-ATPase enzyme system, blocking final step in gastric acid production.

Therapeutic use

Short-term treatment of active duodenal ulcers. Maintenance treatment of healed duodenal ulcers. As part of a multidrug regimen for H. pylori eradication. Short-term treatment of active benign gastric ulcer. Treatment of NSAID-associated gastric ulcer. Short-term treatment of symptomatic gastroesophageal reflux disease. Short-term treatment for all grades of erosive esophagitis. To maintain healing of erosive esophagitis. Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Pregnancy and lactiation implications

Animal studies have not shown teratogenic effects on the fetus. There are as yet no adequate studies in pregnant women. Use during pregnancy only if clearly needed. Not recommended during lactation.

Unlabeled use


Hypersensitivity to lansoprazole, substituted benzimidazoles (i.e. esomeprazole, omeprazole, pantoprazole, rabeprazole), or any component of the formulation.

Warnings and precautions

Might cause atrophic gastritis. No reports of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia. Relief of symptoms does not preclude presence of gastric malignancy. Caution in severe liver dysfunction. Some preparations contain phenylalanine. Administration of proton-pump inhibitors associated with increased risk for developing certain infections (e.g. community-acquired pneumonia).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart